BTZ-043的转化建模预测2A期疗效并评估与贝达喹啉、普托马尼和利奈唑胺在小鼠模型中的药物相互作用
本研究应用小鼠-人转化建模平台,基于BTZ-043单药及与贝达喹啉、普托马尼、利奈唑胺联合的小鼠实验数据和BTZ-043单药临床信息,预测BTZ-043单药在人体2A期的疗效,并评估药物相互作用对联合治疗中BTZ-043贡献的影响。模型预测的人体疗效与观察到的2A期疗效相当;小鼠中与BTZ-043合用使贝达喹啉、普托马尼和利奈唑胺暴露至少降低2倍,模型模拟提示该暴露降低可导致疗效低于观察到的联合用药疗效。结论认为转化建模平台充分预测了BTZ-043单药疗效,若无药物相互作用,BTZ-043与贝达喹啉、普托马尼和利奈唑胺联合预计可提高疗效。
要点
- BTZ-043单药小鼠药代和药效数据分别最佳由二室模型和直接Emax模型描述。
- 模型预测的人体疗效与观察到的2A期疗效相当。
- 与BTZ-043合用使小鼠贝达喹啉、普托马尼和利奈唑胺暴露至少降低2倍。
核心结论
- 转化建模平台充分预测了BTZ-043单药的疗效。
- 若无药物相互作用,BTZ-043与贝达喹啉、普托马尼和利奈唑胺联合预计可提高疗效。
研究设计与样本
- 研究利用BTZ-043单药及与贝达喹啉、普托马尼、利奈唑胺联合的小鼠实验数据,以及BTZ-043单药的临床信息,应用小鼠-人转化建模平台进行预测和模拟。
主要发现
- BTZ-043单药的小鼠药代和药效数据分别最佳由二室模型和直接Emax模型描述。
- 模型预测的人体疗效与观察到的2A期疗效相当。
- 联合治疗中贝达喹啉、普托马尼和利奈唑胺的小鼠药代数据分别最佳由单独开发的单室模型描述。
- 小鼠中与BTZ-043合用与贝达喹啉、普托马尼和利奈唑胺暴露至少降低2倍相关。
- 模型模拟提示观察到的这些药物暴露降低可导致疗效低于观察到的贝达喹啉、普托马尼和利奈唑胺与BTZ-043合用时的疗效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BTZ-043 is a promising novel drug candidate for antituberculosis treatment. This study aimed to apply a previously developed mouse-to-human translational modeling platform for antituberculosis drugs to predict phase 2A outcomes for BTZ-043 in humans and evaluate the impact of observed drug-drug interactions on the contribution of BTZ-043 to combotherapy in a mouse model. METHODS: The study utilized data from mouse experiments for BTZ-043 monotherapy and combotherapy with bedaquiline, pretomanid, and linezolid, and clinical information for BTZ-043 monotherapy. The translational models were applied to predict the colony-forming units as a measure of efficacy in humans treated with BTZ-043 monotherapy and evaluate the effect of BTZ-043 on the pharmacokinetics-pharmacodynamics of combotherapy bedaquiline, pretomanid, and linezolid. RESULTS: The mouse-pharmacokinetic and mouse-pharmacodynamic data for BTZ-043 monotherapy were best described by 2-compartmental and direct Emax models, respectively. The model-based prediction of efficacy in humans was comparable to the observed phase 2A efficacy. Single-compartmental models, developed separately, best described the mouse-pharmacokinetic data for bedaquiline, pretomanid, and linezolid in combotherapy. Coadministration with BTZ-043 was associated with at least a 2-fold reduction in bedaquiline, pretomanid, and linezolid exposures in mice, and model-based simulations suggested that the observed decreases in exposure to these drugs would have resulted in even lower efficacy than what was observed when bedaquiline, pretomanid, and linezolid are coadministered with BTZ-043. CONCLUSIONS: The translational modeling platform adequately predicted the efficacy of BTZ-043 monotherapy. In the absence of drug-drug interactions, coadministration of BTZ-043 with bedaquiline, pretomanid, and linezolid in combotherapy is predicted to improve treatment efficacy. Clinical Trials Registration. NCT0404400.
引用
- Ngara B, Flori L, van Wijk RC, et al. Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models. J Infect Dis. 2025. PMID: 39957252. doi:10.1093/infdis/jiaf088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。